Simplifying Global Compliance
Rule Allows 340B Discounts On Some Orphan Drugs
Washington Drug Letter
HHS has published a final rule specifying that orphan drugs are no longer entirely excluded from cost savings under the 340B program.
To View This Article:
Buy This Article Now
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing